J. European Academy of Dermatology and Venereology, 4 August 2014
Plos Neglected Tropical Diseases 8(11): e3229 (20 November 2014)
A book of methods, aids, and ideas for instructors at the village level
An indispensable resource for health educators, this book provides hundreds of methods, aids, and learning strategies to make health education engaging and effective, encouraging community involvement through participatory edu...cation.
You can download chapter by chapter free of charge
The previous version (2005) is freely available here
more
The scale of West Africa’s Ebola epidemic has been attributed to the weak health systems of affected countries,
their lack of resources, the mobility of communities and their inexperience in dealing with Ebola. This briefing for African Affairs argues that these explanations lack important contex...t. The briefing examines responses to the outbreak and offers a different set of explanations, rooted in the history of the region and the political economy of global health and development. To move past technical discussions of “weak” health systems, it highlights how structural violence has contributed to the epidemic. As part of this, local people – their beliefs, concerns and priorities – have been marginalised. Both the crisis response and post-Ebola ‘reconstruction’ will be strengthened by acknowledgment of its long term structural underpinnings and from a more collaborative inclusion of local people.
more
Interim Assessement Report
The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte...d with the Ebola virus:
BCX4430 (Biocryst);
Brincidofovir (Chimerix);
Favipiravir (Fujifilm Corporation/Toyama);
TKM-100802 (Tekmira);
AVI-7537 (Sarepta);
ZMapp (Leafbio Inc.);
Anti-Ebola F(ab’)2 (Fab’entech).
The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.
more
The document is intended to facilitate the detection, evaluation and management of incident EVD cases in Germany. It primarily addresses public health service staff and health care workers in hospitals, outpatient clinics and emergency services in Germany. It is a work in progress, intended to evolv...e over time. Updated 14 August 2015
more
The document summarizes the infrastructure and activities for Ebola virus disease (EVD) preparedness that are already in place in the Gambia and identifies opportunities for improvement to strengthen the nation’s readiness in the event of an EVD incident.
The Road to Recovery. This synthesis report is based on three national studies on the evolution of the Ebola epidemic and its impact on Guinea, Liberia and Sierra Leone
This Technical Brief focuses on current principles and approaches to Moderate Acute Malnutrition (MAM) management, highlighting key constraints, gaps in knowledge and areas still lacking consensus. It is intended to inform ongoing debates among practitioners, national partners, donors and analysts o...n what information and evidence on best practices are currently available, where the gaps are, and priorities for going forward.
more